In 2008 in this journal, we reported the first broad-based study of the impact of microRNAs on drug activity in cancer cells. Because microRNAs had previously been shown to influence such processes as development, carcinogenesis, cell survival, and apoptosis, it seemed likely that they would also modulate sensitivity and resistance to anticancer drugs. To test that hypothesis, we first analyzed drug-microRNA correlations in data sets we had previously obtained by molecular profiling of the NCI-60, a cancer cell line panel used by the National Cancer Institute to screen compounds for anticancer activity (1) . Because the NCI-60 had already been profiled at the DNA, mRNA, and protein levels more extensively than had any other set of cells (2), we had the advantage of placing our findings for microRNAs in the context of those multiple additional characterizations. Approximately 30 microRNAs showed highly significant correlations with various anticancer agents by quite stringent statistical criteria.
As reported in the MCT article, we then followed up with focused pharmacologic studies of 3 microRNAs previously implicated in cancer biology (let-7i, mir-16, and mir-21) in 3 diverse cell lines from the NCI-60 set. In our experimental system, the expression of individual microRNAs was increased by transfecting the cells with their precursors (which are active) or suppressed by transfecting the cells with antisense oligomers. Overall, we assessed the growth-inhibitory potencies of 14 compounds selected for structural and functional diversity. Altering the levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to fourfold. The effect was most prominent with mir-21; 10 of 28 cell-compound pairs showed significant shifts in growth-inhibitory activity. Varying mir-21 levels changed potencies in opposite directions depending on the class of the agent, indicating differences in mechanism of toxic and protective effects. Overall, the results supported a substantial role for microRNAs in anticancer drug response and suggested novel potential approaches for improving the results of chemotherapy.
Conceptsandfindingsinthestudyhavebeenfollowedup by numerous investigators. The almost 100 papers citing it have included prominent publications in MCT (3) and other AACR journals (4). The study was published in MCT's "Spotlight on Molecular Profiling" series (5), which was established by the Editors in 2005 to highlight publications that feature comprehensive molecular characterization of cancer cells and their pharmacology. The series presaged current projects like The Cancer Genome Atlas enterprise that are doing the same for clinical cancers. In doing so, the series highlighted a natural synergy between -omic and hypothesis-drivenresearch.HeartycongratulationstoMCT on its tenth anniversary of insight, foresight, and seminal contributions to cancer pharmacology and therapeutics.
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